Mirum Pharmaceuticals (MIRM) Set to Announce Earnings on Tuesday

Mirum Pharmaceuticals (NASDAQ:MIRM) will announce its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Mirum Pharmaceuticals has set its FY 2024 guidance at EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The company had revenue of $77.90 million during the quarter, compared to analysts’ expectations of $75.03 million. Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The company’s quarterly revenue was up 107.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.92) EPS. On average, analysts expect Mirum Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM traded up $0.27 during trading hours on Tuesday, reaching $40.72. 138,728 shares of the company traded hands, compared to its average volume of 560,740. The stock has a market capitalization of $1.94 billion, a P/E ratio of -17.66 and a beta of 1.16. The company has a quick ratio of 3.09, a current ratio of 3.28 and a debt-to-equity ratio of 1.34. The business has a fifty day moving average price of $40.10 and a 200-day moving average price of $35.00. Mirum Pharmaceuticals has a 12-month low of $23.14 and a 12-month high of $45.23.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on MIRM shares. Leerink Partners lifted their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. HC Wainwright reissued a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Friday, October 11th. Cantor Fitzgerald lifted their target price on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. Robert W. Baird raised their price target on Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Finally, Evercore ISI lifted their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Ten investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $56.82.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.